16:50 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected donors,...
20:06 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest inhibiting HDAC6 could help treat ALS. In ALS patient-derived motor neurons, inhibition of HDAC6 with two tool compounds or antisense oligonucleotide (ASO)-mediated knockdown decreased axon transport defects...
18:03 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Studies in mice suggest inhibiting HDAC2 could help treat peripheral nerve damage. In a mouse model of sciatic nerve injury, Schwann cell-specific knockout of HDAC2 increased axonal regrowth and sprouting compared with normal...
08:00 , Jan 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Post-traumatic stress disorder (PTSD) Histone deacetylase 2 (HDAC2) Mouse studies suggest HDAC2...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Histone deacetylase 6 (HDAC6) In vitro and mouse studies suggest inhibiting...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Acetylon, Array BioPharma, Celgene deal

Celgene paid $100 million up front in exchange for an exclusive option to acquire Acetylon. If Celgene exercises its option, Acetylon will receive at least $500 million in cash up front and Acetylon shareholders would...
07:00 , Aug 5, 2013 |  BioCentury  |  Strategy

Future-proofing MM

Celgene Corp.'s deal with Acetylon Pharmaceuticals Inc. hinges on the expectation that epigenetic therapy combinations will become mainstays of multiple myeloma treatment and gives Celgene first crack at ACY-1215 - the most advanced HDAC6 inhibitor...
00:09 , Jul 30, 2013 |  BC Extra  |  Top Story

Celgene receives option to acquire Acetylon

Celgene Corp. (NASDAQ:CELG) paid $100 million up front in exchange for an exclusive option to acquire Acetylon Pharmaceuticals Inc. (Boston, Mass.). If Celgene exercises its option, Acetylon will receive at least $500 million in cash...